CA3000032A1 - Antimicrobial polymyxin derivative compounds - Google Patents

Antimicrobial polymyxin derivative compounds Download PDF

Info

Publication number
CA3000032A1
CA3000032A1 CA3000032A CA3000032A CA3000032A1 CA 3000032 A1 CA3000032 A1 CA 3000032A1 CA 3000032 A CA3000032 A CA 3000032A CA 3000032 A CA3000032 A CA 3000032A CA 3000032 A1 CA3000032 A1 CA 3000032A1
Authority
CA
Canada
Prior art keywords
carboxyl
dap
12aryl
compound
side chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3000032A
Other languages
English (en)
French (fr)
Inventor
Kade D. Roberts
Jian Li
Tony Velkov
Roger L. NATION
Philip E. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903961A external-priority patent/AU2015903961A0/en
Application filed by Monash University filed Critical Monash University
Publication of CA3000032A1 publication Critical patent/CA3000032A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3000032A 2015-09-29 2016-09-29 Antimicrobial polymyxin derivative compounds Pending CA3000032A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903961 2015-09-29
AU2015903961A AU2015903961A0 (en) 2015-09-29 Antimicrobial compounds
PCT/AU2016/050915 WO2017054047A1 (en) 2015-09-29 2016-09-29 Antimicrobial polymyxin derivative compounds

Publications (1)

Publication Number Publication Date
CA3000032A1 true CA3000032A1 (en) 2017-04-06

Family

ID=58422486

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3000032A Pending CA3000032A1 (en) 2015-09-29 2016-09-29 Antimicrobial polymyxin derivative compounds

Country Status (7)

Country Link
US (1) US11225505B2 (enExample)
EP (1) EP3356387B1 (enExample)
JP (2) JP7367950B2 (enExample)
CN (1) CN108350034B (enExample)
AU (1) AU2016331658B2 (enExample)
CA (1) CA3000032A1 (enExample)
WO (1) WO2017054047A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944550C (en) 2014-04-01 2021-05-25 Monash University Polymyxin derivatives as antimicrobial compounds
WO2016083531A1 (en) 2014-11-26 2016-06-02 New Pharma Licence Holdings Limited Compounds
US11225505B2 (en) * 2015-09-29 2022-01-18 Monash University Antimicrobial polymyxin derivative compounds
KR102170659B1 (ko) * 2015-11-25 2020-10-27 오사카 유니버시티 레지스트패턴 형성방법 및 레지스트재료
AU2018359018B2 (en) 2017-11-02 2022-11-24 The University Of Queensland Peptide antibiotics
KR20210054500A (ko) 2018-06-25 2021-05-13 스페로 테라퓨틱스, 인코퍼레이티드 화합물
CN109402008B (zh) * 2018-11-15 2021-09-14 中国农业科学院饲料研究所 一株具有吲哚降解能力的不动杆菌tat1-6a及其应用
JP7045520B2 (ja) 2020-01-02 2022-03-31 上海上薬第一生化薬業有限公司 ポリミキシンｂ成分又はその塩、その製造方法及び使用
CN111072757B (zh) * 2020-01-02 2021-10-15 上海上药第一生化药业有限公司 多黏菌素b组分或其盐及其制备方法和应用
WO2025236916A1 (en) * 2024-05-16 2025-11-20 Brii Biosciences, Inc. Compositions and methods for treating infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
WO2006045156A1 (en) 2004-10-29 2006-05-04 Monash University Therapy for multi-drug resistant microorganisms
KR100750658B1 (ko) 2005-12-09 2007-08-20 한국생명공학연구원 폴리믹신 생합성 효소 및 이를 코딩하는 유전자 군
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US8343912B2 (en) * 2008-12-23 2013-01-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) * 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
EP2780357A1 (en) * 2011-11-18 2014-09-24 Novacta Biosystems Limited Polymyxin derivatives
MX360905B (es) * 2013-01-11 2018-11-21 Xellia Pharmaceuticals Aps Polimixinas, composiciones, metodos de preparacion y metodos de uso.
EP2999711B1 (en) 2013-05-22 2022-06-29 Spero Therapeutics, Inc. Polymyxin derivatives and their use in combination therapy together with different antibiotics
KR20160135739A (ko) 2014-03-11 2016-11-28 뉴 파마 라이센스 홀딩스 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
CA2944550C (en) * 2014-04-01 2021-05-25 Monash University Polymyxin derivatives as antimicrobial compounds
US11225505B2 (en) * 2015-09-29 2022-01-18 Monash University Antimicrobial polymyxin derivative compounds

Also Published As

Publication number Publication date
JP2018531241A (ja) 2018-10-25
AU2016331658B2 (en) 2021-04-01
WO2017054047A1 (en) 2017-04-06
JP7367950B2 (ja) 2023-10-24
EP3356387A4 (en) 2019-03-13
CN108350034B (zh) 2022-03-11
AU2016331658A1 (en) 2018-04-19
US20180282374A1 (en) 2018-10-04
EP3356387A1 (en) 2018-08-08
EP3356387B1 (en) 2024-06-26
JP2022009368A (ja) 2022-01-14
US11225505B2 (en) 2022-01-18
CN108350034A (zh) 2018-07-31
NZ741027A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
AU2016331658B2 (en) Antimicrobial polymyxin derivative compounds
JP7117021B2 (ja) 抗菌性化合物としてのポリミキシン誘導体
US8937040B2 (en) Antibiotic compositions for the treatment of gram negative infections
JP2018531241A6 (ja) 抗菌性ポリミキシン誘導体化合物
EP3556769B1 (en) Polymyxin derivative, preparation method and application thereof
JP6471236B2 (ja) ポリミキシン誘導体およびその使用
CA2949328C (en) Low substituted polymyxins and compositions thereof
US12116424B2 (en) Compounds and compositions for modulating Listeria virulence
JP4493891B2 (ja) エキノカンジンの新誘導体、それらの製造方法及びそれらの抗菌剤としての使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210929

EEER Examination request

Effective date: 20210929

EEER Examination request

Effective date: 20210929

EEER Examination request

Effective date: 20210929

EEER Examination request

Effective date: 20210929

EEER Examination request

Effective date: 20210929

EEER Examination request

Effective date: 20210929

EEER Examination request

Effective date: 20210929

EEER Examination request

Effective date: 20210929

EEER Examination request

Effective date: 20210929

EEER Examination request

Effective date: 20210929

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240813

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240813

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240813

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250225

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250613

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250613